Events and Hot Topics

Keep up to date with insights into hot topics and the biggest events
in the UC calendar

Hear from the author: Combining endpoints to assess disease control 

Professor Stefan Schreiber from the University Hospital Schleswig-Holstein, Germany presents a post hoc analysis of the SELECTION trial finding that treatment with filgotinib 200 mg resulted in a higher proportion of patients achieving a combined endpoint of clinical, endoscopic, biological and health-related quality of life outcomes versus placebo (post hoc analysis) at Week 10 in Biologic-Naïve patients (p<0.001) and at Week 58 (p=0.002).

So you think you know JAK: revisiting the JAK–STAT pathway in inflammation with Dr Nick Powell

Dr Nick Powell dives into the role of the JAK-STAT pathway in inflammation.